Head to Head Comparison: Spark Therapeutics (ONCE) & The Competition
Spark Therapeutics (NASDAQ: ONCE) is one of 288 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Spark Therapeutics to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, earnings, profitability and valuation.
Insider and Institutional Ownership
91.0% of Spark Therapeutics shares are owned by institutional investors. Comparatively, 51.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 7.3% of Spark Therapeutics shares are owned by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Spark Therapeutics and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Spark Therapeutics||$20.36 million||-$165.64 million||-12.96|
|Spark Therapeutics Competitors||$464.68 million||$167.54 million||-6.72|
Spark Therapeutics’ competitors have higher revenue and earnings than Spark Therapeutics. Spark Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of recent recommendations for Spark Therapeutics and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Spark Therapeutics Competitors||1379||4469||12295||311||2.63|
Spark Therapeutics currently has a consensus target price of $87.23, indicating a potential upside of 5.31%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 33.85%. Given Spark Therapeutics’ competitors higher probable upside, analysts plainly believe Spark Therapeutics has less favorable growth aspects than its competitors.
This table compares Spark Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Spark Therapeutics Competitors||-4,767.69%||-355.53%||-43.48%|
Volatility and Risk
Spark Therapeutics has a beta of 3.38, meaning that its stock price is 238% more volatile than the S&P 500. Comparatively, Spark Therapeutics’ competitors have a beta of 6.57, meaning that their average stock price is 557% more volatile than the S&P 500.
Spark Therapeutics competitors beat Spark Therapeutics on 7 of the 12 factors compared.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.
Receive News & Stock Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related stocks with our FREE daily email newsletter.